The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
| Autor: | Yu Chin Lee, Ta Peng Wu, Chia Miao Liao, Hsiu Ying Hung, Yen Han Tseng, Sung Yi Chen, Yuh Min Chen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology Lung Neoplasms Disease Pharmacology Tyrosine-kinase inhibitor tyrosine kinase inhibitor 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols 030212 general & internal medicine Epidermal growth factor receptor Medicine Chinese Traditional Research Articles RC254-282 Aged 80 and over biology Standard treatment Neoplasms. Tumors. Oncology. Including cancer and carcinogens Middle Aged ErbB Receptors 030220 oncology & carcinogenesis Adenocarcinoma Female Chinese herbal medicine Adult medicine.medical_specialty medicine.drug_class Pulmonary adenocarcinoma Adenocarcinoma of Lung Disease-Free Survival 03 medical and health sciences Internal medicine medicine Humans Lung cancer Protein Kinase Inhibitors Aged Neoplasm Staging Retrospective Studies adenocarcinoma business.industry Retrospective cohort study medicine.disease respiratory tract diseases lung cancer Complementary and alternative medicine Mutation biology.protein epidermal growth factor receptor business Drugs Chinese Herbal |
| Zdroj: | Integrative Cancer Therapies, Vol 16 (2017) Integrative Cancer Therapies |
| ISSN: | 1552-695X 1534-7354 |
| DOI: | 10.1177/1534735416645181 |
| Popis: | Background. Chinese herbal medicine (CHM) has been used for thousands of year in Eastern countries. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment is the standard treatment in stage IV pulmonary adenocarcinoma patients who had tumor EGFR mutations. This study was to find the efficacy of CHM on lung cancer treatment. Materials and Methods. We retrospectively reviewed chart records of our stage IV EGFR-mutated pulmonary adenocarcinoma patients who received first-line EGFR-TKI treatment from January 2010 to September 2014. Results. Total, 527 patients were studied. Among them, 34 patients received CHM treatment, including 24 patients who received CHM treatment from the beginning of first-line EGFR-TKI treatment and 10 patients who started to receive CHM treatment after their disease had progressed to EGFR-TKI treatment. Median progression-free survival (PFS) of first-line EGFR-TKI treatment was numerically better in patients who also received CHM than those who did not (12.1 months vs 10.5 months, P = .7668). Overall survival of those 24 patient who received CHM treatment together with EGFR-TKI was 30.63 months (95% CI = 11.7 to not reached), compared to 23.67 months in the remaining patients (95% CI = 21.37-26; hazard ratio = 0.75; P = .399). No increase of CHM-related toxicities was found during CHM treatment, compared with EGFR-TKI treatment alone ( P > .05). Conclusion. Alternative CHM treatment during first-line EGFR-TKI treatment did no harm to the patients and PFS and overall survival was numerically better, although not significant, than those patients who did not receive CHM treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|